{"id":612,"date":"2020-10-31T06:39:07","date_gmt":"2020-10-31T06:39:07","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=612"},"modified":"2020-10-31T06:39:07","modified_gmt":"2020-10-31T06:39:07","slug":"27-oct-2020-ivermectin-combination-with-doxycycline-shows-higher-success-rate-when-administered-early","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/27-oct-2020-ivermectin-combination-with-doxycycline-shows-higher-success-rate-when-administered-early\/","title":{"rendered":"(27 Oct 2020) Ivermectin- combination with Doxycycline shows higher success rate when administered early"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.26.20219345v1<\/p>\n<p class=\"\">Randomized controlled study (NCT04591600)&nbsp; on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug\/kg PO of Ivermectin per day for 2-3 days along with 100mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy. Among all patients and among severe patients, 3\/70 (4.28%) and 1\/11 (9%), respectively progressed to a more advanced stage of the disease in the Ivermectin-Doxycycline group versus 7\/70 (10%) and 7\/22 (31.81%), respectively in the control group (P&gt;0.05). The mortality rate was 0\/48 (0%), 0\/11 (0%), and 2\/11 (18.2%) in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin-Doxycycline group versus 0\/48 (0%), and 6\/22 (27.27%) in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (p=0.052). Moreover, the mean time to recovery was 6.34, 20.27, and 24.13 days in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin-Doxycycline group versus 13.66 and 24.25 days in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (P&lt;0.01). Ivermectin with doxycycline reduced the time to recovery and the percentage of patients who progress to more advanced stage of disease; in addition, Ivermectin with doxycycline reduced mortality rate in severe patients from 22.72% to 0%; however, 18.2% of critically ill patients died with Ivermectin and doxycycline therapy. Taken together, the earlier administered Ivermectin with doxycycline, the higher rate of successful therapy.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.26.20219345v1 Randomized controlled study (NCT04591600)&nbsp; on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug\/kg PO of Ivermectin per&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/27-oct-2020-ivermectin-combination-with-doxycycline-shows-higher-success-rate-when-administered-early\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(27 Oct 2020) Ivermectin- combination with Doxycycline shows higher success rate when administered early&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,16],"tags":[38],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/612"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=612"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/612\/revisions"}],"predecessor-version":[{"id":613,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/612\/revisions\/613"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}